Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UroGen Pharma Ltd.URGN · Entity 4466 | Chief Operating Officer | April 26, 2020 | April 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UroGen Pharma Ltd.
Report date April 26, 2020 · Filed April 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,084 |
Ending reported balance
After 2020-04-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-04-26 · Exercise / conversion · Acquired 417 · Balance 10,229 F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Row 2 · 2020-04-27 · Sale · Disposed 145 · Balance 10,084 F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. |
| Restricted Stock Units (RSUs)SEC Table II · derivative / convertible security | Direct | 2,917 |
Reported balance
After 2020-04-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-04-26 · Exercise / conversion · Disposed 417 · Balance 2,917 F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3: The reporting person was granted 5,000 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3: The reporting person was granted 5,000 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2020 Filed Apr 28, 2020 17:43 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 145 | $24.35 | $3,530.75 |
DisclosureSEC source: 0001209191-20-025893 · doc4.xml · nonDerivative · entry 2 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,084 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| April 26, 2020 Filed Apr 28, 2020 17:43 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 417 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025893 · doc4.xml · derivative · entry 3 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,917 Underlying: Ordinary Shares · 417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted 5,000 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted 5,000 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. Read SEC document |
| April 26, 2020 Filed Apr 28, 2020 17:43 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-025893 · doc4.xml · nonDerivative · entry 1 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 19:33 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-009943 · doc4.xml · derivative · entry 3 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,037 Underlying: Ordinary Shares · 1,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019, with the balance vesting in equal quarterly installments thereafter over a period of two years. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019, with the balance vesting in equal quarterly installments thereafter over a period of two years. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 19:33 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 612 | $28.04 | $17,160.48 |
DisclosureSEC source: 0001209191-20-009943 · doc4.xml · nonDerivative · entry 2 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,812 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 19:33 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,759 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-009943 · doc4.xml · nonDerivative · entry 1 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 17:39 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted stock unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006211 · doc4.xml · derivative · entry 2 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Ordinary Shares · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: 1/3rd of the shares underlying the RSU vest on January 31, 2021 and 1/12th of the shares underlying the RSU vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. F3 · derivative.expiration_date: 1/3rd of the shares underlying the RSU vest on January 31, 2021 and 1/12th of the shares underlying the RSU vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 17:39 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock options (right to buy) · Derivative | 15,000 | $0.00 Strike: $29.41 | $0.00 |
DisclosureSEC source: 0001209191-20-006211 · doc4.xml · derivative · entry 1 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires not disclosed F1 · derivative.exercise_date: 1/3rd of the shares underlying the stock option vest on January 31, 2021 and 1/12th of the shares underlying the stock option vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. F1 · derivative.expiration_date: 1/3rd of the shares underlying the stock option vest on January 31, 2021 and 1/12th of the shares underlying the stock option vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. Read SEC document |
| January 27, 2020 Filed Jan 28, 2020 22:14 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 684 | $29.26 | $20,013.84 |
DisclosureSEC source: 0001209191-20-005211 · doc4.xml · nonDerivative · entry 2 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,665 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 26, 2020 Filed Jan 28, 2020 22:14 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 1,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005211 · doc4.xml · derivative · entry 3 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Underlying: Ordinary Shares · 1,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted 5,000 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. F3 · derivative.expiration_date: The reporting person was granted 5,000 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. Read SEC document |
| January 26, 2020 Filed Jan 28, 2020 22:14 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-005211 · doc4.xml · nonDerivative · entry 1 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 21:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-056923 · doc4.xml · derivative · entry 3 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,796 Underlying: Ordinary Shares · 1,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019, with the balance vesting in equal quarterly installments thereafter over a period of two years. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019, with the balance vesting in equal quarterly installments thereafter over a period of two years. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 21:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 608 | $26.00 | $15,806.36 |
DisclosureSEC source: 0001209191-19-056923 · doc4.xml · nonDerivative · entry 2 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,683 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 21:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,759 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-056923 · doc4.xml · nonDerivative · entry 1 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 19:38 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 608 | $31.65 | $19,243.20 |
DisclosureSEC source: 0001209191-19-046282 · doc4.xml · nonDerivative · entry 2 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,532 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 19:38 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-046282 · doc4.xml · derivative · entry 3 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,555 Underlying: Ordinary Shares · 1,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019, with the balance vesting in equal quarterly installments thereafter over a period of two years. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019, with the balance vesting in equal quarterly installments thereafter over a period of two years. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 19:38 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,759 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-046282 · doc4.xml · nonDerivative · entry 1 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| May 14, 2019 Filed May 16, 2019 22:20 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-030594 · doc4.xml · derivative · entry 3 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,314 Underlying: Ordinary Shares · 1,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019, with the balance vesting in equal quarterly installments thereafter over a period of two years. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019, with the balance vesting in equal quarterly installments thereafter over a period of two years. Read SEC document |
| May 14, 2019 Filed May 16, 2019 22:20 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 608 | $37.98 | $23,091.84 |
DisclosureSEC source: 0001209191-19-030594 · doc4.xml · nonDerivative · entry 2 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,381 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| May 14, 2019 Filed May 16, 2019 22:20 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,759 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-030594 · doc4.xml · nonDerivative · entry 1 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| February 14, 2019 Filed Mar 8, 2019 02:44 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 7,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017932 · doc4.xml · derivative · entry 3 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,073 Underlying: Ordinary Shares · 7,034 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019 (with the issuance of the underlying ordinary shares delayed until March 5, 2019), with the balance vesting in equal quarterly installments thereafter over a period of two years. F3 · derivative.expiration_date: The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019 (with the issuance of the underlying ordinary shares delayed until March 5, 2019), with the balance vesting in equal quarterly installments thereafter over a period of two years. Read SEC document |
| February 14, 2019 Filed Mar 8, 2019 02:44 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 2,804 | $37.30 | $104,589.20 |
DisclosureSEC source: 0001209191-19-017932 · doc4.xml · nonDerivative · entry 2 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,230 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| February 14, 2019 Filed Mar 8, 2019 02:44 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 7,034 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-017932 · doc4.xml · nonDerivative · entry 1 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 22:26 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-005805 · doc4.xml · derivative · entry 2 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. F3 · derivative.expiration_date: 33.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter. Read SEC document |
| January 26, 2019 Filed Jan 29, 2019 22:26 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $42.50 | $0.00 |
DisclosureSEC source: 0001209191-19-005805 · doc4.xml · derivative · entry 1 Mullennix Stephen · CIK 0001764139 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2029-01-26 F1 · derivative.exercise_date: 33.33% of the shares underlying the stock option will vest on January 26, 2020 and 12.5% of the remaining shares will vest in eight equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.